Molcure's AI platform is based on evolutionary molecular engineering, next-generation sequencing, and laboratory automation technologies. Together, the companies generated potent, binding antibodies to an undisclosed oncology target for Twist's internal pipeline of antibody candidates.

Twist and Molcure attribute the success in part to a technology agreement between the two firms under which they are working to develop new antibody targets, they said.

Twist acquires iGenomX for $35M
Twist Bioscience has acquired next-generation sequencing library preparation developer iGenomX for $35 million. The deal gives Twist a leg up in...

Twist, Regeneron partner on genetics NGS panel
Twist Bioscience is collaborating with Regeneron subsidiary Regeneron Genetics Center to launch a custom next-generation sequencing (NGS) population genetics...

Twist launches enzymatic fragmentation library prep kit
Twist Bioscience has unveiled its Twist Library Preparation Enzymatic Fragmentation Kit 2.0, an all-in-one solution designed to maximize accuracy and...

Twist announces Q2 financial results
Twist Bioscience announced that revenues grew in the company's second quarter of fiscal 2021, although the firm's net loss also grew.

Twist, Vivlion to generate gRNA libraries for CRISPR applications
Twist Bioscience and Vivlion are collaborating to generate guide RNA (gRNA) libraries for CRISPR genome engineering applications and target discovery...